Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Fremanezumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Teva Presents Positive Ph 3 Trial Data for AJOVY® in Children
    Teva Presents Positive Ph 3 Trial Data for AJOVY® in Children

    04 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/04/2991203/0/en/Teva-Presents-Positive-Efficacy-and-Safety-Data-of-AJOVY-fremanezumab-for-the-Prevention-of-Episodic-Migraine-in-Children-and-Adolescents-from-Phase-3-SPACE-Trial.html

    GLOBENEWSWIRE
    04 Dec 2024
    Share Share
    Teva touts first CGRP success in Phase III paediatric migraine prevention study
    Teva touts first CGRP success in Phase III paediatric migraine prevention study

    19 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240718183120/en/Teva-Announces-First-Phase-3-Evidence-of-Efficacy-and-Safety-of-an-Anti-CGRP-Monoclonal-Antibody-in-Children-in-AJOVY%C2%AE-fremanezumab-SPACE-Trial-for-Prevention-of-Episodic-Migraine

    BUSINESSWIRE
    19 Jul 2024
    Share Share
    Teva's AJOVY® Effective, Safe For Migraine Prevention In China
    Teva's AJOVY® Effective, Safe For Migraine Prevention In China

    11 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240411323269/en

    BUSINESSWIRE
    11 Apr 2024
    Share Share
    New Post Hoc Phase 3 Data Analysis Shows AJOVYReduced Migraine Attacks
    New Post Hoc Phase 3 Data Analysis Shows AJOVYReduced Migraine Attacks

    06 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231205617527/en

    BUSINESSWIRE
    06 Dec 2023
    Share Share
    Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks
    Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks

    17 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231016121295/en

    BUSINESSWIRE
    17 Oct 2023
    Share Share
    US judge overturns Eli Lilly's $176.5 million loss in Teva patent case
    US judge overturns Eli Lilly's $176.5 million loss in Teva patent case

    27 Sep 2023

    // REUTERS

    https://www.reuters.com/legal/us-judge-overturns-eli-lillys-1765-million-loss-teva-patent-case-2023-09-26/

    REUTERS
    27 Sep 2023
    Share Share